Table 4 The risks of cancer related mortality by SF36 vitality score in the EPIC-Norfolk study

Model A: unadjusted full dataset

HR (95 % CI)

1 (reference)

0.97 (0.84–1.16)

1.16 (1.01–1.33)

1.10 (0.95–1.27)

0.043

Model B: unadjusted with removal of baseline CVD/cancer

HR (95 % CI)

1 (reference)

0.95 (0.82–1.10)

1.10 (0.95–1.28)

0.98 (0.83–1.15)

0.237

Model C: confounders

HR (95 % CI)

1 (reference)

0.96 (0.83–1.13)

1.14 (0.96–1.34)

1.09 (0.90–1.32)

0.185

Model D: confounders + Hb

HR (95 % CI)

1(reference)

0.94 (0.79–1.11)

1.16 (0.97–1.38)

1.12 (0.91–1.38)

0.086

Model E: confounders + TSH

HR (95 % CI)

1 (reference)

0.91 (0.75–1.10)

1.13 (0.93–1.38)

0.98 (0.77–1.24)

0.132

Model F: confounders + CRP

HR (95 % CI)

1 (reference)

1.06 (0.88–1.27)

1.18 (0.97–1.44)

1.09 (0.87–1.37)

0.385

Model G: confounders + Hb, CRP,TSH

HR (95 % CI)

1 (reference)

1.04 (0.84–1.29)

1.19 (0.95–1.51)

0.86 (0.65–1.15)

0.081